Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
RADIANCE: Radscopal Radiotherapy Plus Immunotherapy in Metastatic Nasopharyngeal Carcinoma
NCT07756190Phase 2Not yet recruiting
- Sponsor
- Sun Yat-sen University
- Start
- Sep 2026
- Primary completion
- Dec 2029
- Countries
- 1
01
Overview
A Phase 2 trial of sintilimab, ipilimumab in nasopharyngeal carcinoma (NPC), sponsored by Sun Yat-sen University. Planned start Sep 2026; status: not yet recruiting.
02
Drugs
sintilimabipilimumab
03
Conditions
nasopharyngeal carcinoma (NPC)
Beyond the preview
Go deeper on NCT07756190.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07756190.